Corcept Therapeutics Faces Regulatory Setback as FDA Rejects Relacorilant Approval

The FDA’s Regulatory Decision Sends Shockwaves

Corcept Therapeutics [(NASDAQ: CORT)]( experienced a devastating market decline, with share prices falling more than 50% following a regulatory rejection on Tuesday. The setback came after the U.S. Food and Drug Administration issued a complete response letter, declining approval for the company’s flagship drug candidate, relacorilant—a hormone-blocking oral treatment designed to address high blood pressure associated with hypercortisolism.

Understanding the Clinical and Regulatory Challenge

Relacorilant targets a rare hormonal disorder commonly known as Cushing’s syndrome, where patients experience prolonged cortisol elevation—a stress hormone that disrupts normal physiological function. While the FDA acknowledged that the drug successfully met its primary clinical endpoint in late-stage trials, the regulator determined that the pressure on providing substantive efficacy evidence was insufficient. In essence, the FDA’s role as a regulatory symbol of drug safety and effectiveness required additional proof before clearance could be granted.

The agency stated it “could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness,” effectively blocking the medication from reaching the market at this time.

Market Reaction and Investor Implications

The stock price collapse reflects the severity of this regulatory hurdle. For biotech companies dependent on pipeline success, year-end rejections represent critical setbacks to growth trajectories and shareholder value. The magnitude of the decline underscores investor sentiment that this pathway forward requires substantial additional work.

Company’s Path Forward Remains Uncertain

Rather than abandoning the project entirely, Corcept Therapeutics announced plans to engage with FDA officials to explore alternative approval pathways. However, any viable solution would likely necessitate additional clinical trials, prolonging the timeline significantly. Even in optimistic scenarios, securing approval would present a challenging journey ahead.

The regulatory rejection serves as a stark reminder of the risks inherent in biotech development, where clinical promise does not guarantee regulatory success.